Alternate-day fasting and chronic disease prevention: a review of human and animal trials

Krista A Varady and Marc K Hellerstein

ABSTRACT
Calorie restriction (CR) and alternate-day fasting (ADF) represent different forms of dietary restriction. Although the effects of CR on chronic disease prevention were reviewed previously, the effects of ADF on chronic disease risk have yet to be summarized. Accordingly, we review here animal and human evidence concerning ADF and the risk of certain chronic diseases, such as type 2 diabetes, cardiovascular disease, and cancer. We also compare the magnitude of risk reduction resulting from ADF with that resulting from CR. In terms of diabetes risk, animal studies of ADF find lower diabetes incidence and lower fasting glucose and insulin concentrations, effects that are comparable to those of CR. Human trials to date have reported greater insulin-mediated glucose uptake but no effect on fasting glucose or insulin concentrations. In terms of cardiovascular disease risk, animal ADF data show lower total cholesterol and triacylglycerol concentrations, a lower heart rate, improved cardiac response to myocardial infarction, and lower blood pressure. The limited human evidence suggests higher HDL-cholesterol concentrations and lower triacylglycerol concentrations but no effect on blood pressure. In terms of cancer risk, there is no human evidence to date, yet animal studies found decreases in lymphoma incidence, longer survival after tumor inoculation, and lower rates of proliferation of several cell types. The findings in animals suggest that ADF may effectively modulate several risk factors, thereby preventing chronic disease, and that ADF may modulate disease risk to an extent similar to that of CR. More research is required to establish definitively the consequences of ADF.

KEY WORDS Alternate-day fasting, calorie restriction, type 2 diabetes, cardiovascular disease, cancer, animal models, humans

INTRODUCTION
Calorie restriction (CR), defined as a reduction in energy intake without malnutrition, has been shown to increase life span, improve numerous functional indexes, and reduce metabolic risk factors for chronic disease in several mammalian species (1, 2). CR regimens have consisted of reducing food intake to 60–85% of daily energy needs. As an alternative to traditional CR, another dietary regimen, termed alternate-day fasting (ADF), has also been tested. ADF regimens generally involve a “fast day” on which food is consumed ad libitum that alternates with a “feast day” on which food is withheld or reduced. The fast and fast periods are typically 24 h each, but they may vary. A key point about the ADF approach is that overall calorie intake need not be limited; instead, the frequency of food consumption is altered (3).

The purpose of this review is to summarize the relatively sparse but highly suggestive literature on ADF regimens. Although the effects of CR on chronic disease prevention were discussed in reviews conducted in the past few years (4–6), the ability of ADF to alter chronic disease risk has not yet been summarized. In particular, the key question—whether ADF has effects on risk modulation comparable to those of CR—remains uncertain. Accordingly, our objective was to review the evidence from both animal and human trials concerning ADF and the risk of chronic diseases, such as type 2 diabetes mellitus, cardiovascular disease (CVD), and cancer. In addition, when possible, the magnitude of risk reduction due to ADF will be compared with that due to CR.

BENEFITS OF CALORIE RESTRICTION REGIMENS
A large body of evidence for the physiologic benefits and life-extending properties of CR now exists. Restricting daily energy intake by 15–40% has been shown in both animals and humans to improve glucose tolerance and insulin action, which indicates an enhancement in insulin sensitivity (7, 8); to reduce blood pressure and the heart rate, which is consistent with benefits for cardiovascular health (9–11); and to reduce oxidative damage to lipids, protein, and DNA, which implies a protective effect against oxidative stress (12–15). Many other effects of CR have been documented, including increased average and maximal life span (12), reduced incidence of spontaneous and induced cancers (13), resistance of neurons to degeneration (14), lower rates of kidney disease (15), and prolongation of reproductive function (16).

1 From the Department of Nutritional Sciences and Toxicology, University of California at Berkeley, Berkeley, CA.
2 Supported by the Natural Science and Engineering Research Council of Canada.
3 Reprints not available. Address correspondence to KA Varady, Department of Nutritional Sciences and Toxicology, University of California, Berkeley, Morgan Hall, Room 308, Berkeley, CA 94720-3104. E-mail: kvarady@nature.berkeley.edu.
Received October 9, 2006.
Accepted for publication January 15, 2007.
Although the precise mechanisms responsible for such effects are still not clear, several general hypotheses have been proposed—most prominent are the stress resistance hypothesis, the oxidative stress hypothesis, and the induction of a scarcity program hypothesis (3, 17–19). The first hypothesis suggests that, after prolonged dietary restriction, increased resistance to different types of stressors occurs, which permits the cells of many tissues to resist injury induced by genotoxic, metabolic, or oxidative insults (20–22). The second hypothesis proposes more specifically that fewer free radicals are produced in the mitochondria of cells, because dietary restriction generally limits energy utilization, which results in less cellular oxidative damage (3). The third hypothesis proposes that CR induces intrinsic cellular and organismal programs for adaptation to scarcity, which result in the slowing of metabolic processes such as cell proliferation that contribute to senescence; this hypothesis has been strengthened by findings in yeast (19). The effects of ADF on these proposed mechanisms have not been explored as extensively as have the effects of CR, but some evidence has been generated, and that will be reviewed here.

**EFFECT OF ALTERNATE-DAY FASTING ON TYPE 2 DIABETES RISK**

**Animal studies**

To date, 12 studies using animal models have examined the effect of ADF on chronic disease risk (23–34; Table 1). Approximately half of these studies examined variables related to diabetes, such as fasting glucose and insulin concentrations, fat oxidation, degree of insulitis, and occurrence of type 2 diabetes. Fasting glucose concentrations have generally been reported to decrease in response to ADF in animal models. Three studies found reduced circulating glucose concentrations after a 20–24-wk intervention (27, 30), whereas one study reported no effect on glucose concentrations after a 16-wk treatment (24). In the trials that measured insulin concentrations, consistent reductions were noted after ADF regimens that lasted 20 (27) and 24 (28) wk. It is interesting that, in the study of Anson et al (27), both glucose and insulin concentrations decreased to a similar extent in the ADF and the 40% CR groups. Increases in fat oxidation in liver and muscle have also been observed after relatively short periods (8 wk) of ADF (33).

Because impaired fat oxidation may contribute to ectopic accumulation of intracellular lipid and the development of insulin resistance (35), these increases in fat oxidation may increase insulin sensitivity. Also noted by Anson et al was a doubling of the plasma concentrations of β-hydroxybutyrate in the ADF group but no change in the control group. In contrast, concentrations of this metabolite decreased in the 40% CR group but not in the control group (27). These results suggest that high rates of fatty acid oxidation leading to ketogenesis occurred with ADF but not with 40% CR. Moreover, reduced occurrence of insulin-dependent diabetes in response to ADF has been reported by Pedersen et al (30). These authors found that 77% of the BB rats fed ad libitum control diets developed diabetes, whereas only 52% of the animals fasted for 24 h on alternate days became diabetic. The degree of insulitis, however, was not affected, which suggested that the mechanism most likely did not involve modulation of this inflammatory variable (30).

**Human trials**

Risk factors for type 2 diabetes were measured in each of the 3 published human studies of ADF (36–38; Table 2). Evidence from these trials suggests that ADF does not alter fasting concentrations of glucose but may beneficially modulate other indexes of diabetes risk, such as insulin sensitivity. Specifically, Halberg et al (38) observed that, when normal-weight persons fasted for 20-h periods (fast day) and then ate their habitual diet ad libitum on alternate days (feast day), the insulin-mediated glucose uptake increased after 2 wk of intervention, as measured by using the euglycemic-hypersulinemic clamp technique. These results are supported by a study conducted by Heilbronn et al (36), which found that, after 3 wk of ADF, insulin response to a test meal was reduced, which implied improved insulin sensitivity. It is interesting that this effect on insulin sensitivity occurred only in male subjects (36).

Another diabetes risk factor that has shown a sex-specific effect is glucose tolerance. After 3 wk of ADF, women but not men had an increase in the area under the glucose curve (36). This unfavorable effect on glucose tolerance in women, accompanied by an apparent lack of an effect on insulin sensitivity, suggests that short-term ADF may be more beneficial in men than in women in reducing type 2 diabetes risk. However, because minimal data and no longer-term studies are available to support this important hypothesis, more studies are needed. The effect of ADF regimens on insulin concentrations appears equivocal (37, 38). Specifically, Halberg et al (38) found that 2 wk of ADF had no effect on fasting insulin concentrations, whereas Heilbronn et al (37) found that 3 wk of this intervention decreased insulin concentrations, but only after a 32-h fast. Further research examining the time course of ADF effects on such diabetes-related variables could help clarify this matter. Also examined was the responsiveness of skeletal muscle and adipose tissue to ADF (38). A 2-wk ADF regimen had no effect on intramuscular triacylglycerol (IMTG) concentrations in normal-weight men (38). In adipose tissue, an inhibitory effect of insulin on adipose tissue lipolysis was observed after 2 wk of intervention (38). Because increased concentrations of free fatty acids have been implicated in the pathogenesis of type 2 diabetes (39), this decrease in lipolysis and circulating concentrations of free fatty acids may represent an indirect protective effect of ADF on diabetes risk.

**EFFECT OF ALTERNATE-DAY FASTING ON CARDIOVASCULAR DISEASE RISK**

**Animal studies**

As a means of assessing cardiovascular response to ADF, trials in this area have examined heart rate, blood pressure, circulating lipids, and ischemic injury. In a recent study by Mager et al (24), reductions in heart rate were observed in Sprague-Dawley rats after 16 wk of ADF. Similar effects on heart rate were also found by Wan et al (28) after 24 wk of ADF. In both of these trials, treatment-induced decreases in systolic and diastolic blood pressure were noted after 4 wk, and the lower blood pressures persisted throughout the course of the studies. Moreover, the magnitude of the effect on heart rate and blood pressure was similar in the ADF group and a 40% CR group, which suggests that ADF may be as beneficial as CR in modulating these variables (24).
Table 1: Animal trials examining the effect of alternate-day fasting (ADF) on chronic disease risk factors

<table>
<thead>
<tr>
<th>Reference</th>
<th>Animal model</th>
<th>Trial length</th>
<th>Intervention groups</th>
<th>Weight change</th>
<th>DM</th>
<th>CVD</th>
<th>Cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hsieh et al, 2006 (23)</td>
<td>C57BL6 mice Age 2 mo</td>
<td>12 wk</td>
<td>1) ADF (n = 6) 2) 33% CR (n = 6) 3) 33% CR (n = 6) 4) Control (n = 6)</td>
<td>∫-³</td>
<td>Not measured</td>
<td>Not measured</td>
<td>Mammary epithelial cell proliferation: ↓³</td>
</tr>
<tr>
<td>Mager et al, 2006 (24)</td>
<td>SD rats Age 2 mo</td>
<td>16 wk</td>
<td>1) ADF (n = 6) 2) 40% CR (n = 6)</td>
<td>None</td>
<td>Fasting glucose: none</td>
<td>Heart rate: ↓³</td>
<td>Blood pressure: ↓³</td>
</tr>
<tr>
<td>Ahmet et al, 2005 (25)</td>
<td>SD rats Age 2 mo</td>
<td>12 wk</td>
<td>1) ADF (n = 30) 2) Control (n = 30)</td>
<td>∫⁻³</td>
<td>Not measured</td>
<td>MI induced (wk 12) 24 h after MI: MI size: 50% smaller²</td>
<td>Apoptotic myocytes number 75% less²</td>
</tr>
<tr>
<td>Descamps et al, 2005 (26)</td>
<td>Wistar rats Age 6 mo</td>
<td>16 wk</td>
<td>1) ADF (n = 15) 2) Control (n = 15)</td>
<td>None</td>
<td>Not measured</td>
<td>Not measured</td>
<td>Incidence of lymphoma: 0%³</td>
</tr>
<tr>
<td>Anson et al, 2003 (27)</td>
<td>C57BL6 mice Age 2 mo</td>
<td>20 wk</td>
<td>1) ADF (n = 8) 2) 40% CR (n = 8) 3) Control (n = 8)</td>
<td>None</td>
<td>Fasting glucose: ↑³</td>
<td>Fasting insulin: ↑³</td>
<td>β-Hydroxybutyrate: ↑³</td>
</tr>
<tr>
<td>Wan et al, 2003 (28)</td>
<td>SD rats Age 3 mo</td>
<td>24 wk</td>
<td>1) ADF (n = 8) 2) 2DG suppl (n = 8) 3) Control (n = 8)</td>
<td>∫⁻³</td>
<td>Fasting glucose: ↑³</td>
<td>Fasting insulin: ↑³</td>
<td>β-Hydroxybutyrate: ↑³</td>
</tr>
<tr>
<td>Rocha et al, 2002 (29)</td>
<td>Wistar rats Age 2 mo</td>
<td>48 wk</td>
<td>1) ADF (n = 12) 2) Control (n = 12)</td>
<td>None</td>
<td>Not measured</td>
<td>MI induced (wk 12) 24 h after MI: MI size: 50% smaller²</td>
<td>Apoptotic myocytes number 75% less²</td>
</tr>
<tr>
<td>Pedersen et al, 1999 (30)</td>
<td>BB rats Age 3 mo</td>
<td>20 wk</td>
<td>1) ADF (n = 44) 2) Fast for 24 h 2wxk (n = 40) 3) Control (n = 77)</td>
<td>∫⁻³</td>
<td>DM incidence: 52%;⁴ (DM incidence in control group: 79%)</td>
<td>Degree of insulin: none</td>
<td>Fasting glucose: ↑³</td>
</tr>
<tr>
<td>Krizova and Simek, 1996 (32)</td>
<td>C17/B1-10 mice Age 2 mo</td>
<td>8 wk</td>
<td>1) ADF–regular diet on feed day (n = 10) 2) ADF–40% fat diet on feed day (n = 10) 3) Control (n = 10)</td>
<td>↑³ (both groups)</td>
<td>Not measured</td>
<td>Total cholesterol: ↓³</td>
<td>Triacylglycerols: ↓³</td>
</tr>
<tr>
<td>Krizova and Simek, 1996 (33)</td>
<td>C17/B1-10 mice Age 2 mo</td>
<td>8 wk</td>
<td>1) ADF–regular diet on feed day (n = 8) 2) ADF–high-fat diet on feed day (n = 8) 3) Control (n = 10)</td>
<td>↑³ (both groups)</td>
<td>Liver fat oxidation: ↓³</td>
<td>Muscle fat oxidation: ↓³</td>
<td>Not measured</td>
</tr>
<tr>
<td>Goodrick et al, 1990 (31)</td>
<td>C57 or A/J mice Age 1 mo</td>
<td>Until death</td>
<td>1) ADF starting at age 2 mo (n = 30) 2) ADF starting at age 6 mo (n = 30) 3) ADF starting at age 10 mo (n = 30) 4) Control (n = 30)</td>
<td>↓³ (C57 groups) None (A/J groups)</td>
<td>Not measured</td>
<td>Not measured</td>
<td>C57BL/6 mice: ↑³ (all ADF groups) A/J mice: ↑³ (2-mo group) Life span: none (6-mo group) Life span: ↑³ (10-mo group)</td>
</tr>
<tr>
<td>Seigel et al, 1988 (34)</td>
<td>Fisher rats Age 3 mo</td>
<td>2 wk</td>
<td>1) ADF (n = 24) 2) Control (n = 24)</td>
<td>None</td>
<td>Not measured</td>
<td>Not measured</td>
<td>After tumor inoculation (wk 1): 1/24 ADF rats survived for 10 d after inoculation (compared to 3/24 controls)</td>
</tr>
</tbody>
</table>

¹ 2DG suppl, supplementation with 2-deoxy-D-glucose; BB, Bio-breeding; BW, body weight; CR, calorie-restricted; CVD, cardiovascular disease; DEN, diethylnitrosamine; DM, diabetes mellitus; GSH/GSSG, glutathione/glutathione disulfide; IGF-1, insulin-like growth factor-1; MDA, malondialdehyde; ROS, reactive oxygen species; SD, Sprague-Dawley; SOD, superoxide dismutase.
² ADF group, fed ad libitum for 24 h and then fasted for 24 h; control group, fed ad libitum daily.
³ Posttreatment values of ADF group significantly different from posttreatment values of control group, P < 0.05.
⁴ Posttreatment values significantly different from baseline values within the ADF group, P < 0.05.

In addition, Krizova and Simek (32) observed decreases in circulating lipid concentrations, and, after 8 wk of ADF, both total cholesterol and triacylglycerol concentrations decreased in adult mice. Moreover, the cardiac myocyte response to myocardial infarction (MI) induction has been studied by Ahmet et al (25). MI was induced by coronary artery ligation after 12 wk of ADF or control ad libitum diet in Sprague-Dawley rats. At 24 h after MI induction, the number of apoptotic myocytes in the affected area was one-fourth that in the ad libitum–fed controls, and the size of the MI in the ADF group was half that in the ad libitum–fed controls. Also noted was a distinct reduction in neutrophil infiltration, which suggested a decrease in inflammatory response (25).
The protective effect of ADF on cancer survival was first described by Seigel et al (34). In this study, 3–4-mo-old rats were administered an ADF regimen beginning 1 wk before inoculation with MAT 13762 acites tumor cells (34). Twelve of the 24 rats (50%) in the diet-restricted group survived 10 d after tumor inoculation, in comparison with only 3 of 24 animals (12.5%) in the control group, which had been fed ad libitum (34). The response to ADF of certain biomarkers of cancer risk, ie, insulin-like growth factor-1 (IGF-1), has also been investigated (27, 28), but the results have been inconsistent. Whereas Anson et al (27) reported increases in IGF-1 in response to 20 wk of ADF, Wan et al (28) reported a clear decrease after 24 wk of treatment. IGF-1 is a potent promoter of cell proliferation and has been shown to decrease in response to CR (40). The animals in the study of Anson et al (27) did not lose any weight, whereas animals in the study of Wan et al (28) did lose weight; the lack of overall net negative energy balance may explain the different IGF-1 responses in those studies.

More recently, the protective effect of the ADF restriction protocol on age-associated lymphoma and hepatocarcinogenesis was examined in mice (26). After 16 wk, the incidence of lymphoma in OF1 mice administered an ADF regimen was 0% and that in the control group was 33%. Because the ADF group mice consumed roughly the same total amount of food as the control mice, the efficacy of ADF was independent of total calorie intake (26). Also noted in that study was a significant, treatment-induced increase in spleen mitochondrial superoxide dismutase (SOD) activity, which was associated with reduced mitochondrial generation of reactive oxygen species (ROS). The effect of ADF on hepatocarcinogenesis has also been examined (29) after 4 wk of ad libitum feeding. In that study, Wistar rats were injected with diethylnitrosamine to initiate liver carcinogenesis and then fed on alternate days for 48 wk. When compared with ad libitum feeding, ADF inhibited the development of preneoplastic lesions and also decreased the number and size of liver nodules (29). These findings strongly support the hypothesis that long-term ADF may exert an antipromotional effect on experimental carcinogenesis, as has been shown in many studies of CR. Moreover, strong physiologic evidence in favor of the antipromotional effects of ADF was recently reported by Hsieh et al (23). After 12 wk of treatment, reduced rates of proliferation of several cell types, including mammary epithelial cells, skin epithelial cells (keratinocytes), and splenic T-cells, was observed (23). These changes induced by ADF were similar to, though not quite as potent as, those seen in the CR groups.

ADF regimens have also been shown to increase mean and maximal life span in certain strains of mice (31). When ADF regimens were initiated in C57BL/6j mice at ages 2, 6, and 10 mo, body weight decreased and maximal life span was extended (31). It is interesting that, when the same ADF protocol was administered to A/J mice, body weight was not affected, and life span was increased only in the group that began ADF at age 2 mo (31). These findings suggest that ADF-induced changes in body weight and maximal life span may be strongly influenced by genotype and the age at which ADF is initiated.

**TABLE 2**

Human trials examining the effect of alternate-day fasting (ADF) on chronic disease risk factors

<table>
<thead>
<tr>
<th>Reference</th>
<th>Subjects</th>
<th>Trial length</th>
<th>ADF protocol</th>
<th>Weight change</th>
<th>Effect of ADF on risk factors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heilbronn et al, 2005 (36)</td>
<td>n = 16 Normal-weight men and women Age 20–55 y</td>
<td>3 wk</td>
<td>Fast day: 24-h fast Feast day: ad libum feeding No control group</td>
<td>Body weight: $-2.1 \pm 0.3$ kg</td>
<td>Glucose clearance: ↑ (women), none (men) Insulin sensitivity: none (women), ↑ (men) CVD: none Mitochondrial biogenesis: none Fat oxidation genes: none</td>
</tr>
<tr>
<td>Heilbronn et al, 2005 (37)</td>
<td>n = 16 Normal-weight men and women Age 20–55 y</td>
<td>3 wk</td>
<td>Fast day: 24-h fast Feast day: ad libum feeding No control group</td>
<td>Body weight: $-2.5 \pm 0.5$ kg Fat mass: $+4.0$ g</td>
<td>Fasting glucose: none Fasting insulin after 32-h fast: ↑ Insulin-mediated glucose uptake: ↑ Insulin-induced lipolysis inhibition: ↑ Fasting glucose: none Fasting insulin: none IMTG: none</td>
</tr>
</tbody>
</table>

1 CVD, cardiovascular disease; DM, diabetes mellitus; IL-6, interleukin 6; IMTG, intramuscular triacylglycerol; RMR, resting metabolic rate; TNF-α, tumor necrosis factor-α.

2 Posttreatment values were significantly different from baseline values within the ADF group, $P < 0.05$. 

Human trials

Heilbronn et al (37) examined the effect of ADF on CVD risk. When human subjects fasted on alternate days for a short period (3 wk), circulating concentrations of HDL cholesterol increased, whereas triacylglycerol concentrations decreased (37). It is possible that these effects resulted from the decreases in body weight (2.5%) and fat mass (4.0%) observed in these subjects, who were unable to consume sufficient calories on the feast day to maintain an isocaloric state (37). It is interesting that the shifts in lipid concentrations were shown to be sex specific: ie, only the women had an increase in HDL-cholesterol concentrations, and only the men had a decrease in triacylglycerol concentrations (37). There is no clear explanation for these sex-based differences. The effect of ADF on blood pressure was also examined in this study. After 3 wk of intervention, neither systolic nor diastolic blood pressure changed in either the male or female subjects (37). This study included only normotensive persons, however. It will be of interest in future studies to examine the effect of this dietary regimen on blood pressure in other patient groups, such as those who are hypertensive, overweight, obese, and hyperlipidemic.

**EFFECT OF ALTERNATE-DAY FASTING ON CANCER RISK: ANIMAL TRIALS**

The protective effect of ADF on cancer survival was first described by Seigel et al (34). In this study, 3–4-mo-old rats were administered an ADF regimen beginning 1 wk before inoculation with MAT 13762 acites tumor cells (34). Twelve of the 24 rats (50%) in the diet-restricted group survived 10 d after tumor inoculation, in comparison with only 3 of 24 animals (12.5%) in the control group, which had been fed ad libum (34). The response to ADF of certain biomarkers of cancer risk, ie, insulin-like growth factor-1 (IGF-1), has also been investigated (27, 28), but the results have been inconsistent. Whereas Anson et al (27) reported increases in IGF-1 in response to 20 wk of ADF, Wan et al (28) reported a clear decrease after 24 wk of treatment. IGF-1 is a potent promoter of cell proliferation and has been shown to decrease in response to CR (40). The animals in the study of Anson et al (27) did not lose any weight, whereas animals in the study of Wan et al (28) did lose weight; the lack of overall net weight and maximal life span may be strongly influenced by genotype and the age at which ADF is initiated.
EFFECT OF ALTERNATE-DAY FASTING ON OTHER METABOLIC VARIABLES: HUMAN TRIALS

The effect of short-term ADF regimens on other metabolic variables, such as body temperature, resting metabolic rate (RMR), and various hormone and cytokine concentrations, has also been examined in human subjects (36, 37). In the study by Heilbronn et al (37), neither body temperature nor RMR was affected by 3 wk of treatment. On the other hand, overall fat oxidation was shown to increase by an average of 15 g/d over the course of the trial, according to indirect calorimetry. The authors also observed a positive correlation between fat oxidation and weight loss, which suggested that those subjects with a greater ability to oxidize fat may have lost more weight (37). Thus, whether the weight loss noted is a result of ADF may depend on a person’s ability to oxidize fat. Heilbronn et al (36) also examined treatment-induced changes in the expression of certain skeletal muscle genes involved in fat oxidation, including β-hydroxyacyl CoA dehydrogenase, fatty acid translocase, pyruvate dehydrogenase kinase 4, carnitine palmitoyltransferase 1, and uncoupling protein 3, as well as the expression of genes implicated in mitochondrial biogenesis, including peroxisome-proliferator-activated receptor-gamma co-activator 1, nuclear respiratory factor 1, and cytochrome C. They reported that a 3-wk treatment had no effect on the expression of any of these genes. The response of circulating concentrations of certain adipokines—ie, adiponectin, leptin, interleukin 6 (IL-6), and tumor necrosis factor (TNF-α)—has also been examined (38). Concentrations of leptin, IL-6, and TNF-α did not change in response to ADF; in contrast, concentrations of adiponectin increased by 37% (38). Cnop et al (41) and Higashiura et al (42) both reported that circulating concentrations of adiponectin are positively correlated with insulin sensitivity, which suggests a possible role of this adipokine in the insulin-sensitizing effect noted in the present trial (38).

SUMMARY OF FINDINGS: ALTERNATE-DAY FASTING IN HUMAN AND ANIMAL TRIALS

Some discrepancies between human and animal ADF data are evident. With regard to the effect of ADF on the risk of type 2 diabetes mellitus, the results to date from human trials have been inconsistent, whereas the animal evidence suggests favorable alterations. Fasting glucose concentrations in rodents, for example, consistently were lower after 20 wk of treatment (27, 28, 30), whereas, in humans, no effect was seen after 2–3 wk of ADF (37, 38). It may be that longer intervention periods are required to alter glucose concentrations in human subjects. In the case of fasting insulin concentrations, equivocal findings were noted in humans (37, 38), whereas consistent decreases have been seen in animals (27, 28). Moreover, animal data indicate that ADF is just as efficacious in decreasing fasting glucose and insulin concentrations as is daily CR (27). Although neither glucose nor insulin concentrations were affected in the brief human trials carried out to date, it is interesting that findings such as increased insulin-mediated glucose uptake and reduced adipose tissue lipolysis have been reported (38). In animal models, fatty acid oxidation in liver and muscle is increased with ADF (33); this may indicate that ectopic accumulation of intracellular lipid could be decreased, which in turn may lead to improved insulin sensitivity (43). Nevertheless, it should be noted that, in obese human subjects, CR does not affect intramyocellular lipid content but does result in decreased lipid accumulation in liver (44). Complementary to this evidence, the incidence of type 2 diabetes risk was lower in rodents fed on alternate days than in ad libitum–fed controls (30). In sum, the favorable effects noted in animal studies suggest that prolonged ADF is a beneficial means of lowering type 2 diabetes risk. Results from human studies, however, are less clear. It seems reasonable to expect that ADF will improve insulin sensitivity in humans, but the conflicting findings make it difficult to be certain about this. Longer intervention trials (ie, ≥20 wk) in human subjects may help to clarify this issue.

Although overall beneficial modulations in risk factors for vascular disease have been found, with respect to blood pressure, the evidence from animal studies has shown a consistent decrease in both systolic and diastolic readings (24, 28), whereas data from human trials have shown no effect on either variable (37). One possible explanation for this inconsistency may be the differences in the duration of intervention. Because an effect on blood pressure readings was identified only after a 4-wk treatment in animals (24, 28), treatment for 3 wk in the human study may not have been long enough. Alternatively, weight loss, ie, negative energy balance, may be required for a blood pressure effect in humans. In the case of circulating lipid concentrations, beneficial modulations have been noted in both human and animal studies (32, 37). Specifically, human data show treatment-induced increases in HDL-cholesterol concentrations and reductions in triglycerol concentrations (37), and results in rodents show decreases in total cholesterol and triglycerol concentrations (32). Also shown, although only in rodent models, were improvements in cardiac response to MI induction (25) and decreases in heart rate (24, 28). In addition, the decreases in heart rate and blood pressure induced by ADF were similar to those induced by CR (24). Taken together, these improvements suggest that ADF may help reduce the risk of CVD.

To date, the direct effect of ADF on cancer has been tested only in animal models. Most of those trials suggest a pronounced beneficial effect on cancer risk factors, including substantial decreases in lymphoma incidence (26), increases in spleen SOD activity accompanied by reductions in ROS generation (26), inhibition of hepatic preneoplastic lesion development (29), and a greater survival rate after tumor inoculation (34). The physiologic evidence of clear reductions in proliferation rates of several cell types—including mammary epithelial cells, keratinocytes, and splenic T-cells—induced by ADF regimens also supports the antiproliferative actions of this intervention (23). The antiproliferative mechanism remains unknown, however, because the effects of ADF on IGF-1 concentrations have been inconsistent (27, 28). Nevertheless, most of these studies have reported a protective effect, so it is reasonable to propose that ADF will prove to be an effective means of decreasing cancer risk. Studies in human subjects are still required to answer this important question.

An interesting but unresolved issue is the effect of ADF on body weight. Body weight has been shown to be highly variable in response to ADF in both human and animal models. In some animal models, when ADF regimens have been applied in the short term, no effect on body weight has been noted after 2 wk (34), whereas gains in weight were noted in other trials after 8 wk (32, 33). It is possible that the animals in the 8-wk trial may have overcompensated for the lack of food on the fast day by eating more than twice their average daily intake on the feast day. In other studies, when ADF regimens were administered for 12 wk,
body weight was found to decrease (23, 25), but, when ADF regimens were administered for 16 wk, no effect on body weight was observed (24, 26). Trials examining the effects of long-term (>20 wk) ADF in animals (28–31) have fairly consistently found decreases in body, although the study by Anson et al (27) did not. Such findings suggest that the animals were unable to consume twice their daily food intake on the feast day for longer periods, which resulted in a loss of body weight. There clearly is variability in the capacity of animals, even within the same strain of mouse, to compensate for a fast day on the feast day (27). A variety of factors, such as housing conditions, palatability, or energy density of diet, and genetics can be hypothesized as influencing compensation. Understanding the factors controlling compensation is an important area for future research.

The effect of ADF on body weight in humans is difficult to infer because of the very short trial durations and the small number of studies published to date. As was seen in animal trials, 2 wk of ADF had no effect on body weight in normal-weight human subjects (38). Nevertheless, when the intervention period in humans was extended to 3 wk, a decrease in body weight (≈2.5 kg) was noted (36, 37). This decrease in body weight may have resulted from an inability to consume an adequate amount of food on the feast day to sustain body weight. Similar findings were noted in animals, but only after much longer trial durations (>20 wk). An important study design issue is whether weight loss should be prevented in human ADF studies by “forced” maintenance of caloric intake. Forcing maintenance of intake may produce harmful effects over the long term, so this approach cannot currently be recommended. It is also possible that weight loss in humans following an ADF regimen will prove to be minor or transient. In contrast, striving for full compensation of caloric intake (ie, no weight loss) in studies lasting only weeks or a few months is unlikely to have significant adverse health consequences. The absence of weight loss would allow useful comparisons and distinctions between ADF and CR. These issues will require consideration by investigators who conduct future human trials with ADF.

CONCLUSIONS

Findings to date from both human and animal experiments indicate that ADF may effectively decrease the risk of CVD, whereas results from animal studies suggest a protective effect on cancer risk. In terms of diabetes prevention, animal data suggest a beneficial effect, but human data have been equivocal. However, it is important to note that the human studies examined in this review are limited; they all lacked control groups and used short trial lengths. Future studies with longer trials and including control groups are needed to answer these important questions. The effect of ADF regimens in insulin-resistant or diabetic populations also should be determined, because they could help to clarify the role of ADF as a treatment for preexisting diabetes rather than as a protection against diabetes.

Moreover, human ADF trials in modestly overweight persons, who are at greater risk of chronic disease, are warranted. In this context, it is important to note that the control animals in both the CR and ADF studies are likely to have been obese, because they were fed ad libitum.

ADF regimens also may be as efficacious as daily CR in improving certain indexes of risk of type 2 diabetes and CVD, although the number of studies directly comparing the 2 regimens is small. Further analysis of the mechanisms responsible for beneficial effects of ADF is clearly warranted, particularly if these effects occur in the absence of negative energy balance. Novel mediators and therapeutic strategies may thereby be uncovered. Finally, it seems intuitively likely that persons will find it easier to fast or reduce intake on alternate days than to reduce their intake every day. For this reason, ADF regimens may allow better compliance than would CR regimens and may represent an attractive area for investigation.

It will also be important to understand whether the mechanisms by which ADF protects against chronic disease risk are similar to those of CR. Indirect evidence suggests that the 2 regimens may share mechanisms. For instance, the study of Descamps et al (26) reported increases in spleen mitochondrial SOD activity accompanied by decreases in mitochondrial generation of ROS as a result of ADF. Such findings suggest that ADF may act by increasing resistance to oxidative insult, which is a key feature of the stress resistance hypothesis.

In summary, this still nascent literature suggests that ADF may effectively modulate metabolic and functional risk factors, thereby preventing or delaying the future occurrence of common chronic diseases, at least in animal models. The effect of ADF on chronic disease risk in normal-weight human subjects remains unclear, however, as do the mechanisms of action. Much work remains to be done to understand this dietary strategy fully.

The authors’ responsibilities were as follows—KAV: collected, analyzed, and interpreted the data and wrote the manuscript; MKH: contributed to the analysis and interpretation of the data. Neither of the authors had a personal or financial conflict of interest.

REFERENCES


